Iovance Biotherapeutics, Inc. $IOVA Shares Bought by Profund Advisors LLC

Profund Advisors LLC grew its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 149.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 260,660 shares of the biotechnology company’s stock after acquiring an additional 156,253 shares during the quarter. Profund Advisors LLC owned about 0.07% of Iovance Biotherapeutics worth $712,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of IOVA. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Iovance Biotherapeutics during the third quarter valued at $27,000. Arcataur Capital Management LLC acquired a new position in shares of Iovance Biotherapeutics during the fourth quarter valued at $29,000. M&T Bank Corp bought a new stake in shares of Iovance Biotherapeutics during the fourth quarter valued at about $31,000. SBI Securities Co. Ltd. raised its stake in shares of Iovance Biotherapeutics by 169.1% during the fourth quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 7,269 shares in the last quarter. Finally, Federated Hermes Inc. raised its stake in shares of Iovance Biotherapeutics by 67.6% during the third quarter. Federated Hermes Inc. now owns 15,111 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 6,095 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Trading Up 11.1%

NASDAQ IOVA opened at $4.11 on Friday. The stock’s 50-day moving average price is $3.63 and its two-hundred day moving average price is $3.04. The company has a market cap of $1.84 billion, a PE ratio of -4.33 and a beta of 0.69. Iovance Biotherapeutics, Inc. has a 1 year low of $1.66 and a 1 year high of $5.63.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). The firm had revenue of $71.43 million for the quarter, compared to the consensus estimate of $77.84 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The business’s revenue for the quarter was up 44.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.36) EPS. Research analysts forecast that Iovance Biotherapeutics, Inc. will post -0.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IOVA. Barclays lifted their price objective on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Wall Street Zen upgraded shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Citizens Jmp upgraded shares of Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price objective on the stock in a research note on Tuesday, March 3rd. The Goldman Sachs Group reiterated a “sell” rating and issued a $2.00 price target on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Finally, Chardan Capital dropped their price target on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Iovance Biotherapeutics presently has an average rating of “Hold” and a consensus target price of $8.43.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.